Journal of the Royal College of Physicians of Edinburgh, 2013 Psoriasis is a chronic, immune-mediated inflammatory skin disease affecting 1.3–2.2% of the UK population.1 Most commonly, psoriasis is characterised by well-demarcated, red plaques with adherent scale with a predilection for the scalp and extensor surfaces of the limbs.
L, Burfield, A D, Burden
openaire +4 more sources
Early morphea simulating patch-stage mycosis fungoides in two cases
Dermatology Reports, 2018 Morphea is a skin disorder characterized by thickening of dermis and subcutaneous tissues and loss of adnexal structures. In the early inflammatory stage of morphea, diagnostic histological findings are absent and this may lead to confusion with other ...
Hamid R. Ghasemi Basir +3 more
doaj +1 more source
T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva (TM)): Mechanisms of action [PDF]
, 2004 Psoriasis is a chronic, incurable, auto-immune disorder with cutaneous manifestations. New evidence on the central role of the immune system in the pathogenesis of psoriasis increasingly provides insight into pathogenic steps that can be modulated to ...
Caro, I. +7 more
core +1 more source
Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study [PDF]
, 2018 Background: Few studies have compared the efficacy of switching to adalimumab in the real-life setting in plaque psoriasis patients. Objective: To evaluate the effect of adalimumab in psoriasis patients previously treated with other biologics.
Armesto +40 more
core +1 more source
Dysregulated Peripheral Invariant Natural Killer T Cells in Plaque Psoriasis Patients
Frontiers in Cell and Developmental Biology, 2022 Background: Psoriasis is a common immune-mediated skin disease that involves T-cell-mediated immunity. Invariant natural killer T (iNKT) cells are a unique lymphocyte subpopulation that share properties and express surface markers of both NK cells and T ...
Yifan Hu +25 more
doaj +1 more source
Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52-week PRO-long study [PDF]
, 2015 Background: Topical therapies are the mainstay of treatment for psoriasis vulgaris. The fixed combination of calcipotriol (Cal) 50 mu g/g plus betamethasone 0.5 mg/g (as dipropionate; BD) is a first-line topical treatment and available as a gel or ...
Hol, CW, Lambert, Jo, Vink, J
core +1 more source
Treatment recommendations for psoriatic arthritis [PDF]
, 2008 Objective: To develop comprehensive recommendations for the treatment of the various clinical manifestations of psoriatic arthritis (PsA) based on evidence obtained from a systematic review of the literature and from consensus opinion.
Boehncke, Wolf-Henning +14 more
core +3 more sources
Frontiers in Immunology, 2023 BackgroundPsoriasis is a chronic inflammatory skin disease with effects that extend beyond the skin. Insulin resistance (IR) has been associated with psoriasis, but it remains unclear how indicators related to the triglyceride glucose (TyG) index, which ...
Dawei Huang +13 more
doaj +1 more source
Frontiers in Medicine, 2023 Ustekinumab is a biological therapy that has been approved for treating moderate-to-severe psoriasis. Although injection site reactions, nasopharyngitis, headaches, and infections are the common adverse events associated with ustekinumab, the development
Luyang Kong +13 more
doaj +1 more source
Microarray analyses demonstrate the involvement of type i interferons in psoriasiform pathology development in D6-deficient mice [PDF]
, 2013 The inflammatory response is normally limited by mechanisms regulating its resolution. In the absence of resolution, inflammatory pathologies can emerge, resulting in substantial morbidity and mortality.
Baldwin, H.M. +9 more
core +1 more source